$4.040
+0.200 (+4.94%)At close
ZURA News
ZURA Events
Zura Bio Files $700M Mixed Securities Shelf
Zura Bio files $700M mixed securities shelf
Zura Medical to Report TibuSURE Study Results in H1 2027
"Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027," said Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer of Zura. "We continue to believe deeply in tibulizumab's potential to address complex immune biology and unmet needs across indications, including in PMR, where we will be starting the NEXUS-PMR study by end of year. With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab's unique potential."
Zura Cash and Cash Equivalents Reach $187.7 Million
As of September 30, 2026, Zura had cash and cash equivalents of $187.7 million. Zura expects that its existing cash and cash equivalents are sufficient to support planned operations through at least the end of 2028.
Sandeep Kulkarni: Strong Execution on tibulizumab Programs, Funding Expected Through 2028
"The second quarter was marked by strong execution across our tibulizumab programs, with enrollment now complete in both TibuSHIELD and TibuSURE-each exceeding its initial enrollment target-underscoring growing conviction in dual IL-17 and BAFF inhibition," said Sandeep Kulkarni, CEO. "We are excited to nominate polymyalgia rheumatica as the third indication for tibulizumab, a debilitating disorder with high unmet need and important evidence supporting the roles of both IL-17 and BAFF. With cash expected to fund planned operations through at least the end of 2028, we believe we are well positioned-operationally, financially, and scientifically-as we approach our first topline readout in the fourth quarter of this year."
Tenaya Therapeutics Appoints Eric Hyllengren as CFO
Tenaya Therapeutics (TNYA) announced the appointment of Eric Hyllengren as CFO, effective July 13. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development. He most recently served as CFO and executive VP of Zura Bio (ZURA).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.